ETrade Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

ETrade Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-1,885	Closed	-$49K	–	766
2014 Q1	$49K	Buy	1,885 +58	+3%	+$1.45K	﹤0.01%	566
2013 Q4	$46K	Sell	1,827 -174	-9%	-$3.88K	﹤0.01%	476
2013 Q3	$41K	Sell	2,001 -190	-9%	-$3.92K	﹤0.01%	456
2013 Q2	$44K	Buy	+2,191	New	+$38.9K	﹤0.01%	393

Other funds holding IPXL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ETrade Capital Management's IPXL Position: Q2 2014 in Review

ETrade Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2014, closing a stake of 1,885 shares — an estimated $49K sold.

ETrade Capital Management first reported a position in IPXL in Q2 2013 and held it in 4 quarters. The position peaked at $49K in Q1 2014. 185 funds tracked by Wall St. Rank hold IPXL as of Q2 2014.

ETrade Capital Management reported no remaining Impax Laboratories, Inc. position as of Q2 2014 after selling out during the quarter.
ETrade Capital Management sold 1,885 Impax Laboratories, Inc. shares in Q2 2014, an estimated $49K.
ETrade Capital Management first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 4 quarters.
ETrade Capital Management's Impax Laboratories, Inc. position peaked at $49K in Q1 2014.
185 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2014.

Based on ETrade Capital Management's 13F filing for Q2 2014, filed 13 Aug 2014.